Allogene Therapeutics : ASH 2021 Conference Call Presentation

The Potential Innovation of Allogeneic CAR T Therapy in Hematologic Cancers

American Society of Hematology (ASH) December 13, 2021

Legal Disclaimers

To the extent statements contained in this Presentation are not descriptions of historical facts regarding Allogene Therapeutics, Inc. ("Allogene," "we," "us," or "our"), they are forward-looking statements reflecting management's current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance, or achievements to be materially different from those anticipated by such statements. You can identify forward-looking statements by words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this Presentation include, but are not limited to, statements regarding: clinical outcomes, which may materially change as more patient data become available; the timing and ability to progress the clinical trials of ALLO-501,ALLO-501A,ALLO-316,ALLO-715 and ALLO-605, including the timing and ability to resolve the clinical hold and progress to a Phase 2 clinical trial of ALLO-501A; the ability to manufacture AlloCAR T™ therapies for use in clinical trials; and the potential benefits of AlloCAR T™ therapy. Various factors may cause differences between Allogene's expectations and actual results as discussed in greater detail in Allogene's filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 10-Q for the quarter ended September 30, 2021.

Caution should be exercised when interpreting results from separate trials involving separate product candidates. There are differences in the clinical trial design, patient populations, follow-up times, and the product candidates themselves, and the results from the clinical trials of autologous products may have no interpretative value on our existing or future results.

Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This Presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

2

Allogene: A Leader in Allogeneic Cell Therapy

3

years since inception

• foundational platform technologies:
• • AlloCAR TTM
  • TurboCARTM
  • iPSC
  • Allogeneic manufacturing

~300

employees

$862

million

in cash, cash equivalents and investments as of Sept 30, 2021

• clinical trials including four "firsts", subject to FDA review:
• • First pivotal trial
  • First solid tumor trial
  • First combo trial
  • First TurboCAR™ trial

130based on reported data, more patients have been treated

> with Allogene's AlloCAR TTM therapies than any other allogeneic CAR T therapy in development

1

singular focus on allogeneic cell therapy

3

Putting Heme Malignancies "On Wheels"

Sears Motor Buggy

The Model T

Autologous CAR T

AlloCAR T

In the 1900s, the automobile had been invented. Sears sold them out of their catalogue, but obtaining one required waiting for delivery, uncrating the vehicle and self assembly.

Ford's Model T changed everything and put society on wheels. It was easier to drive, more powerful and - most famously - created at scale on an assembly line and ready to drive.

Major step forward for patients with late-stage blood cancers but requires time and complexity - waiting for a manufacturing slot, harvesting of cells, tailored manufacturing, cell delivery and infusion.

Like the Model T AlloCAR Ts have the potential to change everything: greater on demand access scalable manufacturing and simpler logistics.

4

Understanding Market Dynamics to Change How We "Think" About CAR T

KEY QUESTIONS

1. How are the unique benefits of allogeneic valued?
2. Can benefits of an allogeneic therapy be leveraged to expand the market for cell therapy?

3. How do physicians view consolidated dosing?

1. How important is time to treatment?

PHYSICIAN PREFERENCE

Ability to optimize efficacy and treat all eligible patients with an off-the-shelf therapy are highly valued

Yes, ease of dosing and favorable safety provide opportunity to reach outpatient and community settings

Physicians comfortable providing either 1 or 2 doses of CAR T therapy

A higher likelihood of patients receiving treatment and faster time to onset can extend the reach of CAR T

Allogene Market Research: Data on File

5